Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Central States Research LLC

Neither a doctor nor a teaching hospital

Research payments

$2,824,806

238 payments

Through program year 2025, Central States Research LLC is reported as receiving $2,824,806 in research payments, across 238 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $1,152,977 33
2024 Research $143,082 4
2023 Research $271,313 7
2022 Research $94,848 12
2021 Research $394,878 62
2020 Research $504,484 96
2019 Research $263,225 24

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eisai Inc. $1,313,205 44 payments
  2. AbbVie, Inc. $583,950 91 payments
  3. Biogen, Inc. $423,228 4 payments
  4. Allergan Inc. $200,214 43 payments
  5. Genentech, Inc. $139,924 18 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $64,688 7 payments
  7. Otsuka Pharmaceutical Development & Commercialization, Inc. $39,511 9 payments
  8. Celgene Corporation $25,079 4 payments
  9. ACADIA Pharmaceuticals Inc $14,917 6 payments
  10. Teva Pharmaceuticals USA, Inc. $11,278 7 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial) $1,140,890 29 payments
  2. A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $423,228 4 payments
  3. M16-046 $258,906 31 payments
  4. A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid $172,315 15 payments
  5. M18-891 $170,982 21 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $107,735 13 payments
  7. Gantenerumab Open Label Extension $83,160 13 payments
  8. Proof of concept and DRF in BPD $65,001 9 payments
  9. Gantenerumab Mild Ad $56,764 5 payments
  10. A Phase 3, Multicenter, Open-Label 40-Week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Migraine $56,007 15 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $912 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record